Granted Major European Patent For Ph1 Adc Payload Platform
12/05/2026 14:25
May 12 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS PLC - GRANTED MAJOR EUROPEAN PATENT FOR PH1 ADC PAYLOAD PLATFORM AKARI THERAPEUTICS PLC - AKTX-101 PHASE 1 FIRST-IN-HUMAN TRIAL TARGETED BY MID-2027 Source text: ID:nGNX6v3d0m Further company coverage: AKTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics